228 related articles for article (PubMed ID: 24005572)
21. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
22. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
23. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
24. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
25. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.
Paradiso A; Mangia A; Chiriatti A; Tommasi S; Zito A; Latorre A; Schittulli F; Lorusso V
Ann Oncol; 2005 May; 16 Suppl 4():iv14-19. PubMed ID: 15923415
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
28. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
30. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
31. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
Petrillo M; Ferrandina G; Fagotti A; Vizzielli G; Margariti PA; Pedone AL; Nero C; Fanfani F; Scambia G
Ann Surg Oncol; 2013 Nov; 20(12):3955-60. PubMed ID: 23838915
[TBL] [Abstract][Full Text] [Related]
32. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD
Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976
[TBL] [Abstract][Full Text] [Related]
33. Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
Vandenput I; Capoen A; Coenegrachts L; Verbist G; Moerman P; Vergote I; Amant F
Int J Gynecol Cancer; 2011 Aug; 21(6):1071-7. PubMed ID: 21792013
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Takaya H; Nakai H; Murakami K; Tobiume T; Suzuki A; Mandai M; Matsumura N
Int J Clin Oncol; 2018 Aug; 23(4):698-706. PubMed ID: 29572761
[TBL] [Abstract][Full Text] [Related]
36. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
Kondo E; Nimura R; Maki S; Kaneda M; Nii M; Yoshida K; Tabata T; Ikeda T
Anticancer Res; 2021 Aug; 41(8):4157-4161. PubMed ID: 34281887
[TBL] [Abstract][Full Text] [Related]
39. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
